Nkarta reports FY2022 net loss of $113.8M; cash $354.9M; NKX101/019 updates in 2023

Nkarta, Inc.

Net loss of $113.8M ($2.61 diluted EPS) for FY2022; Q4 loss $32.6M ($0.67).
Cash and investments total $354.9M; management expects runway to fund operations into 2025.
R&D expenses $90.9M (FY) and $26.8M (Q4); G&A $28.1M (FY) and $8.1M (Q4).
NKX101: 60% CR in AML at higher doses; additional data expected H1 2023.
NKX019: 70% CR in B-cell malignancies; dose expansion enrolling; updated data expected in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.